Group 1 - The company expects a significant increase in consolidated revenue for the period ending mid-2025, projecting at least RMB 500 million, which represents an increase of at least approximately 387% compared to the revenue of about RMB 103 million for the six months ending June 30, 2024 [1] - The company anticipates a turnaround from a net loss of RMB 1.238 billion for the six months ending June 30, 2024, to a net profit of no less than RMB 50 million for the mid-2025 period [1] - The company also expects to shift from an adjusted net loss (non-IFRS) of RMB 251 million for the six months ending June 30, 2024, to an adjusted net profit (non-IFRS) of at least RMB 120 million for the mid-2025 period, marking the company's first half-year profit [1] Group 2 - The anticipated improvement in financial performance for the mid-2025 period is primarily due to the collaboration with DoveTree Medicines LLC and its affiliates, leveraging an end-to-end AI drug discovery platform and comprehensive "AI + robotics" technology [2] - The company received an upfront payment of USD 51 million, which has been recognized as revenue for the mid-2025 period and significantly contributes to the company's earnings during the reporting period [2] - According to the agreement terms with DoveTree, the company is entitled to receive further payments, which will be recognized as revenue in batches in the future [2]

Group 1 - The company expects consolidated revenue for the period ending mid-2025 to be no less than RMB 500 million, representing an increase of at least approximately 387% compared to the revenue of about RMB 103 million for the six months ending June 30, 2024 [1] - The company anticipates a turnaround from a net loss of RMB 1.238 billion for the six months ending June 30, 2024, to a net profit of no less than RMB 50 million for the mid-2025 period [1] - The company also expects an adjusted net profit (non-IFRS) of no less than RMB 120 million for the mid-2025 period, compared to an adjusted net loss (non-IFRS) of RMB 251 million for the six months ending June 30, 2024 [1] Group 2 - The expected improvement in financial performance for mid-2025 is primarily due to the collaboration with DoveTree Medicines LLC and its affiliates, leveraging an end-to-end AI drug discovery platform and comprehensive "AI + robotics" technology [2] - The company received an upfront payment of USD 51 million, which has been recognized as revenue for the mid-2025 period and significantly contributes to the company's revenue during the reporting period [2] - According to the agreement with DoveTree, the company is entitled to receive further payments, which will be recognized as revenue in batches in the future [2]

Core Viewpoint - The company anticipates significant financial improvement for the six months ending June 30, 2025, with a projected comprehensive income of at least RMB 500 million, marking an increase of at least 387% compared to RMB 103 million for the same period in 2024 [1][2] Financial Performance Expectations - The company expects to turn a loss into profit, with a projected net profit of at least RMB 50 million for the six months ending June 30, 2025, compared to a net loss of RMB 1.238 billion for the same period in 2024 [1] - The adjusted net loss (non-IFRS) for the six months ending June 30, 2024, was RMB 251 million, which is expected to turn into an adjusted net profit (non-IFRS) of at least RMB 120 million for the 2025 mid-term period [1] Revenue Growth Drivers - The anticipated financial improvement is primarily attributed to the collaboration with DoveTree Medicines LLC and its affiliates, leveraging an end-to-end AI drug discovery platform and comprehensive "AI + Robotics" technology [2] - The company received an upfront payment of USD 51 million, which has been recognized as revenue for the six months ending June 30, 2025, significantly contributing to the expected revenue growth [2] - Further payments are expected under the agreement with DoveTree, which will be recognized as revenue in future installments [2]

Core Viewpoint - The article highlights the significant partnership between JingTai Technology and DoveTree, marking a record order scale in the AI and robotics drug development sector, with a total order value of approximately HKD 470 billion [1][3]. Group 1: Company Overview - JingTai Technology was founded by three MIT PhD graduates and has received backing from notable investors, including Tencent's founder Ma Huateng [3]. - The company aims to leverage AI technology to revolutionize drug discovery, significantly reducing the time and cost associated with traditional drug development processes [7][9]. Group 2: Partnership Details - The collaboration with DoveTree, a prominent biopharmaceutical company, involves the development of multiple innovative drug assets, with DoveTree holding exclusive global rights for commercialization [5][9]. - The partnership is expected to enhance the credibility of JingTai's AI drug development model, as it gains recognition from established figures in the pharmaceutical industry [9][10]. Group 3: Financial Implications - JingTai has received an initial payment of approximately HKD 4 billion and is set to receive additional payments totaling around HKD 462 billion, linked to project milestones and sales [12][13]. - The company reported a revenue of approximately HKD 266 million for the year ending December 31, 2024, with significant R&D expenditures, indicating a focus on long-term growth despite current losses [12]. Group 4: Market Position and Future Prospects - JingTai has established itself as a key player in the pharmaceutical industry, with 16 of the top 20 global pharmaceutical companies as clients [9][10]. - The company is diversifying its business model beyond pharmaceuticals into materials science and agriculture, which may lead to shorter return cycles and increased revenue streams [19][20].

晶泰控股(02228.HK)发布公告，于2025年6月底，本公司的间接全资附属公司深圳晶泰科技有限公司(深 圳晶泰)与 DoveTree Medicines LLC及其联属公司(DoveTree)订立了一份最终协议(经不时修订，"最终协 议")。根据该协议，本集团将利用其基于"AI+机器人"的端到端人工智能药物发现平台，为 DoveTree选 定的多个主要针对肿瘤学、免疫及炎症疾病、神经系统疾病及代谢失调领域的靶点，发现和开发小分子 及抗体类候选药物，及DoveTree将获得以上产品全球范围的独家开发和商业化权利。 本文源自：金融界AI电报 ...

Core Viewpoint - JingTai Holdings (02228) has entered into a final agreement with DoveTree Medicines LLC and its affiliates to utilize its AI and robotics-based drug discovery platform for developing drug candidates targeting oncology, immunology, inflammation, neurological disorders, and metabolic disorders [1] Group 1 - The agreement allows JingTai to discover and develop small molecule and antibody candidates for multiple key targets selected by DoveTree [1] - DoveTree will receive exclusive global development and commercialization rights for the products developed under this agreement [1] - As of the announcement date, JingTai has received an initial payment of $51 million under the terms of the final agreement [1]